Evidence map›Paper›PMID 41229377›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.

Jianchao Wang, Wenfang Zhang, Jiyang Zhang, Chenhui Zhao, Wei Zhang, Menghan Fang, Fangfang Chen, Zhida Wu, Xiaoya Xu, Ziqing Yu and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jianchao WangDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Wenfang ZhangDepartment of Pathology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China.
Jiyang ZhangDepartment of Clinical and Translational Research, 3D Medicines Inc., Shanghai, 201114, China.
Chenhui ZhaoDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, 210029, China.
Wei ZhangDepartment of Clinical and Translational Research, 3D Medicines Inc., Shanghai, 201114, China.ORCID https://orcid.org/0000-0003-2867-259X
Menghan FangDepartment of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Fangfang ChenDepartment of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Zhida WuDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Xiaoya XuDepartment of Clinical and Translational Research, 3D Medicines Inc., Shanghai, 201114, China.ORCID https://orcid.org/0000-0002-2992-320X
Ziqing YuDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Qiong ZhuDepartment of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Yi ShiDepartment of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Dadong ZhangDepartment of Clinical and Translational Research, 3D Medicines Inc., Shanghai, 201114, China.ORCID https://orcid.org/0000-0001-6419-8886
Xiaofeng ChenDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, 210029, China.
Gang ChenDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.ORCID https://orcid.org/0000-0003-2540-8232

Funding

Innovation of Science and Technology Fujian Province 2023Y9425National Natural Science Foundation of China 82404069Science and Technology Program of Fujian Province 2025J011190
6 · The paper itself

Abstract

Current understanding of immune characteristics in gastric cancer remains limited for guiding clinical practice, particularly immunotherapy. This study aims to elucidate the multidimensional landscape of tumor microenvironment in gastric cancer, identify predictive biomarkers potentially associated with favorable immunotherapy response, and propose a precision stratification framework to inform therapeutic strategies. This study introduces a novel immune classification system tumor immune microenvironment (TIME)-inflamed, TIME-desert, and TIME-excluded), and characterize the cellular and molecular characteristics of each subtype. TIME-inflamed tumors exhibit significantly higher infiltration of immune cells in tumor regions, as well as increased expression of inflamed-genes. TIME-desert tumors display minimal immune cell infiltration and feature abnormal microvasculature. TIME-excluded subtype is defined by immune cell accumulation outside the tumor with ineffective intratumoral infiltration, prominent fibroblast activity, and collagen deposition. Application of this immune classification system to stratify gastric cancer within the SPACE cohort successfully demonstrates potential for predicting favorable outcomes of a subset of "cold tumor" patients upon receiving combined immunotherapy and chemotherapy. The findings contribute to advancing the classification of gastric cancer from traditional histopathological subtyping to functional immunological subtyping, providing a valuable scientific foundation for precise patient stratification and the development of individualized immunotherapy strategies in clinical practice.

Indexed as

ImmunotherapyStomach NeoplasmsTumor MicroenvironmentBiomarkers, TumorFemaleHumansMaleMultiomicsPhenotypeBiomarkers, Tumorgastric cancerimmunological phenotypingimmunotherapymicroenvironmentmultiplex immunohistochemistry

Identifiers

PMID41229377
PMCPMC12866680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.